Your browser doesn't support javascript.
loading
Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC).
Rafii, Hanadi; Garnier, Federico; Ruggeri, Annalisa; Ionescu, Irina; Ballot, Caroline; Bensoussan, Danièle; Chabannon, Christian; Dazey, Bernard; De Vos, John; Gautier, Eric; Giraud, Christine; Larghero, Jérome; Cras, Audrey; Mialou, Valérie; Persoons, Virginie; Pouthier, Fabienne; Thibert, Jean-Baptiste; Dalle, Jean-Hugues; Michel, Gerard; Kenzey, Chantal; Volt, Fernanda; Rocha, Vanderson; Bay, Jacques-Olivier; Rubio, Marie-Thérèse; Faucher, Catherine; Marry, Evelyne; Gluckman, Eliane.
Afiliação
  • Rafii H; Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France. hanadi.rafii-elayoubi@aphp.fr.
  • Garnier F; Monacord, Centre Scientifique de Monaco, Monaco, Monaco. hanadi.rafii-elayoubi@aphp.fr.
  • Ruggeri A; Agency of Biomedecine, Saint Denis La Plaine, France.
  • Ionescu I; Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France.
  • Ballot C; Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Bensoussan D; Agency of Biomedecine, Saint Denis La Plaine, France.
  • Chabannon C; Cell Therapy unit, Etablissement Français du Sang Hauts de France Normandie, site de LILLE - Belfort, Lille, France.
  • Dazey B; Tissue Engineering and Cell Therapy unit, Regional University hospital, Nancy, France.
  • De Vos J; Paoli-Calmettes Institute, Departement of Cancer Biology, Inserm CBT1409, Marseille, France.
  • Gautier E; Cell Therapy unit, Etablissement Français du Sang, Bordeaux, France.
  • Giraud C; Cell Therapy unit, University hospital, Montpellier, France.
  • Larghero J; Cell Therapy unit, Etablissement Français du Sang, Créteil, France.
  • Cras A; Department of Hematology and Cell Therapy, Etablissement Français du Sang, University hospital, Poitiers, France.
  • Mialou V; Cell Therapy Unit and Cord Blood Bank, AP-HP, Hôpital Saint Louis, Paris, France.
  • Persoons V; Cell Therapy Unit and Cord Blood Bank, AP-HP, Hôpital Saint Louis, Paris, France.
  • Pouthier F; Cell Therapy unit, Etablissement Français du Sang, hopital E. Herriot, Lyon, France.
  • Thibert JB; Cell Therapy and Tissue Engineering unit, Etablissement Français du Sang, Grenoble, France.
  • Dalle JH; Cell and Tissue Engineering unit, Etablissement Francais du Sang, Besançon, France.
  • Michel G; Cell Therapy unit, Etablissement Français du Sang, Rennes, France.
  • Kenzey C; Hopital Robert Debré, Assistance Publique - Hôpitaux de Paris, Paris, France.
  • Volt F; Aix-Marseille University and La Timone Children's Hospital, Marseille, France.
  • Rocha V; Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France.
  • Bay JO; Monacord, Centre Scientifique de Monaco, Monaco, Monaco.
  • Rubio MT; Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France.
  • Faucher C; Monacord, Centre Scientifique de Monaco, Monaco, Monaco.
  • Marry E; Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France.
  • Gluckman E; Department of Hematology, Clinics Hospital, University of São Paulo Medical School, São Paulo, Brazil.
Bone Marrow Transplant ; 56(10): 2497-2509, 2021 10.
Article em En | MEDLINE | ID: mdl-33990703
The public French Cord Blood Banks Network was established in 1999 with the objective of standardizing the practices governing umbilical cord blood (UCB) banking in France. The Network adopted a strategy to optimize its inventory and improve the quality of its banked units based on a quality improvement process using outcome data regularly provided by Eurocord. This study aimed to describe the results, over 10 years, of UCBT facilitated by a national network that used the same criteria of UCB collection and banking and to assess how modifications of banking criteria and unit selection might influence transplant outcomes. Nine hundred and ninety-nine units (593 single-unit and 203 double-unit grafts) were released by the Network to transplant 796 patients with malignant (83%) and non-malignant (17%) diseases. Median cell dose exceeded 3.5 × 107 TNC/kg in 86%. There was a trend to select units more recently collected and with higher cell dose. Neutrophil engraftment was 88.2% (85.7-90.7) and 79.3% (72.6-86.5) respectively for malignant and non-malignant diseases with a trend to faster recovery with higher cell doses. The respective 3-year transplant-related mortality were 31.1% (27.5-35.1) and 34.3% (27.0-43.5). OS was 49% ± 4 in malignant and 62% ± 4 in non-malignant disorders. In multivariate analysis, cell dose was the only unit-related factor associated with outcomes. Our results reflect the benefit on clinical outcomes of the strategy adopted by the Network to bank units with higher cell counts.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Transplante de Células-Tronco de Sangue do Cordão Umbilical Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Transplante de Células-Tronco de Sangue do Cordão Umbilical Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article